Table 3 Pathologic information on 200 cases of follicular lymphoma in young patients according to anatomic locations and age subgroups
From: Follicular lymphoma in young adults: a clinicopathological and molecular study of 200 patients
Extranodal | Nodal FL (age groups) | Nodal | ||||||
|---|---|---|---|---|---|---|---|---|
FL | ≤25 | 26–30 | 31–35 | 36–40 | Total | FL+DLBCL | Total | |
Total | 20 | 11 | 18 | 59 | 85 | 173 | 7 | 200 |
Grade (%(+)) | ||||||||
1 | 55 (11) | 55 (6) | 39 (7) | 46 (27) | 46 (39) | 46 (79) | 0 | 45 (90) |
2 | 25 (5) | 18 (2) | 44 (8) | 37 (22) | 29 (25) | 33 (57) | 14 (1) | 32 (63) |
3a | 10 (2) | 9 (1) | 11 (2) | 15 (9) | 20 (17) | 17 (29) | 29 (2) | 16 (33) |
3b | 10 (2) | 18 (2) | 6 (1) | 2 (1) | 5 (4) | 4 (8) | 57 (4) | 7 (14) |
Histological findings (%(+)) | ||||||||
Fibrosis | ||||||||
1+ | 0 | 0 | 17 (3) | 7 (4) | 11 (9) | 9 (16) | 0 | 8 (16) |
2+ | 5 (1) | 0 | 11 (2) | 7 (4) | 6 (5) | 6 (11) | 29 (2) | 7 (14) |
3+ | 5 (1) | 0 | 6 (1) | 3 (2) | 0 | 2 (3) | 14 (1) | 2 (5) |
Mantle zone | 15 (3) | 0 | 22 ((4) | 20 (12) | 14 (12) | 16 (28) | 14 (1) | 16 (32) |
Diffuse areas | 10 (2) | 18 (2) | 11 (2) | 8 (5) | 8 (7) | 9 (16) | 100 (7) | 12 (25) |
TAM | ||||||||
1+ | 0 | 0 | 17 (3) | 7 (4) | 7 (6) | 7 (13) | 0 | 6 (13) |
2+ | 5 (1) | 9 (1) | 0 | 2 (1) | 8 (7) | 5 (8) | 0 | 4 (9) |
3+ | 0 | 9 (1) | 0 | 0 | 1 (1) | 1 (2) | 0 | 1 (2) |
FDC meshwork (%(+/tested)) | ||||||||
Preserved | 14 (2/14) | 20 (2/10) | 43 (6/14) | 44 (24/54) | 53 (34/64) | 41 (66/162) | 33 (2/6) | 43 (70/162) |
Disrupted | 21 (3/14) | 40 (4/10) | 29 (4/14) | 33 (18/54) | 30 (19/64) | 29 (45/162) | 17 (1/6) | 30 (49/162) |
Absent | 64 (9/14) | 40 (4/10) | 29 (4/14) | 22 (12/54) | 17 (11/64) | 19 (31/162) | 50 (3/6) | 27 (43/162) |
Immunophenotype (%(+/tested)) | ||||||||
CD10 | 89 (16/18) | 91 (10/11) | 86 (12/14) | 95 (54/57) | 89 (70/79) | 91 (146/161) | 71 (5/7) | 91 (167/184) |
MUM1 | 7 (1/15) | 40 (4/10) | 15 (2/13) | 2 (1/50) | 11 (7/62) | 10 (14/135) | 50 (3/6) | 12 (18/156) |
BCL6 | 100 (17/17) | 100 (11/11) | 100 (16/16) | 100 (55/55) | 92 (69/75) | 96 (151/157) | 100 (7/7) | 97 (175/181) |
BCL2 | 94 (17/18) | 73 (8/11) | 94 (17/18) | 98 (58/59) | 96 (82/85) | 95 (165/173) | 100 (7/7) | 95 (189/198) |
CD23 | 36 (5/14) | 20 (2/10) | 21 (3/14) | 28 (15/54) | 20 (13/64) | 28 (33/142) | 33 (2/6) | 25 (40/162) |
MDM2 (≥20%) | 13 (2/15) | 30 (3/10) | 23 (3/13) | 10 (5/50) | 10 (6/62) | 15 (20/135) | 67 (4/6) | 17 (26/156) |
Ki-67 (≥50%) | 15 (3/20) | 40 (4/10) | 11 (2/18) | 24 (14/59) | 26 (21/82) | 24 (41/169) | 100 (7/7) | 26 (51/196) |
FISH rearrangement (%(+/conclusive)) | ||||||||
BCL2 | 82 (9/11) | 50 (4/8) | 82 (9/11) | 87 (28/32) | 70 (33/47) | 75 (74/98) | 0 (0/3) | 74 (83/112) |
BCL6 | 0 (0/10) | 33 (2/6) | 12 (1/8) | 16 (5/31) | 24 (11/46) | 21 (19/91) | 50 (2/4) | 20 (21/105) |
